BACKGROUND: Immunotherapy advances for the treatment of cutaneous melanoma question its efficacy in treating anorectal mucosal melanoma (ARMM). We aimed to identify the prevalence, current management, and overall survival (OS) for ARMM. METHODS: Review of patients with ARMM from 2004 to 2015 National Cancer Database. Factors associated with immunotherapy were identified using multivariable logistic regression. The primary outcome was 2- and 5-year OS. Subgroup analysis by treatment type was performed. RESULTS: A total of 1331 patients were identified with a significant increase in prevalence (2004: 6.99%, 2015: 10.53%). ARMM patients were older, white, on Medicare, and from the South. The most common treatment was surgery (48.77%), followed by surgery + radiation (11.75%), surgery + immunotherapy (8.68%), and surgery + chemotherapy (8.68%). 16.93% of patients received immunotherapy, with utilization increasing (7.24%: 2004, 21.27%: 2015, p < 0.001). Patients who received immunotherapy had a significantly better 2-year OS (42.47% vs. 49.21%, p < 0.001), and other therapies did not reveal a significant difference. Adjusted analysis showed no difference in 2- and 5-year OS based on therapy type. CONCLUSION: The prevalence of ARMM has increased. The use of immunotherapy has increased substantially. Some survival benefit with the administration of immunotherapy may exist that has yet to be revealed. A more aggressive treatment paradigm is warranted.
BACKGROUND: Immunotherapy advances for the treatment of cutaneous melanoma question its efficacy in treating anorectal mucosal melanoma (ARMM). We aimed to identify the prevalence, current management, and overall survival (OS) for ARMM. METHODS: Review of patients with ARMM from 2004 to 2015 National Cancer Database. Factors associated with immunotherapy were identified using multivariable logistic regression. The primary outcome was 2- and 5-year OS. Subgroup analysis by treatment type was performed. RESULTS: A total of 1331 patients were identified with a significant increase in prevalence (2004: 6.99%, 2015: 10.53%). ARMM patients were older, white, on Medicare, and from the South. The most common treatment was surgery (48.77%), followed by surgery + radiation (11.75%), surgery + immunotherapy (8.68%), and surgery + chemotherapy (8.68%). 16.93% of patients received immunotherapy, with utilization increasing (7.24%: 2004, 21.27%: 2015, p < 0.001). Patients who received immunotherapy had a significantly better 2-year OS (42.47% vs. 49.21%, p < 0.001), and other therapies did not reveal a significant difference. Adjusted analysis showed no difference in 2- and 5-year OS based on therapy type. CONCLUSION: The prevalence of ARMM has increased. The use of immunotherapy has increased substantially. Some survival benefit with the administration of immunotherapy may exist that has yet to be revealed. A more aggressive treatment paradigm is warranted.
Authors: Adrienne Callahan; William F Anderson; Sital Patel; Jill S Barnholtz-Sloan; Jeremy S Bordeaux; Margaret A Tucker; Meg R Gerstenblith Journal: Dermatol Surg Date: 2016-01 Impact factor: 3.398
Authors: Alfonso Quintás-Cardama; Alexander J Lazar; Scott E Woodman; Kevin Kim; Merrick Ross; Patrick Hwu Journal: Nat Clin Pract Oncol Date: 2008-10-21
Authors: K B Kim; O Eton; D W Davis; M L Frazier; D J McConkey; A H Diwan; N E Papadopoulos; A Y Bedikian; L H Camacho; M I Ross; J N Cormier; J E Gershenwald; J E Lee; P F Mansfield; L A Billings; C S Ng; C Charnsangavej; M Bar-Eli; M M Johnson; A J Murgo; V G Prieto Journal: Br J Cancer Date: 2008-08-19 Impact factor: 7.640
Authors: So-Woon Kim; Young Il Kim; Bilal Mustafa; Mi-Ju Kim; Gowun Jeong; Sung-Min Ahn; Seok-Byung Lim; Chang Sik Yu; Jin Cheon Kim; Seung-Mo Hong; In Ja Park Journal: Mod Pathol Date: 2020-07-24 Impact factor: 7.842
Authors: Priyadharsini Nagarajan; Jin Piao; Jing Ning; Laura E Noordenbos; Jonathan L Curry; Carlos A Torres-Cabala; A Hafeez Diwan; Doina Ivan; Phyu P Aung; Merrick I Ross; Richard E Royal; Jennifer A Wargo; Wei-Lien Wang; Rashmi Samdani; Alexander J Lazar; Asif Rashid; Michael A Davies; Victor G Prieto; Jeffrey E Gershenwald; Michael T Tetzlaff Journal: Mod Pathol Date: 2019-08-05 Impact factor: 7.842
Authors: Mohammad Adileh; Jonathan B Yuval; Shan Huang; Alexander N Shoushtari; Felipe Quezada-Diaz; Emmanouil P Pappou; Martin R Weiser; Julio Garcia-Aguilar; J Joshua Smith; Philip B Paty; Garrett M Nash Journal: Dis Colon Rectum Date: 2021-05 Impact factor: 4.585
Authors: Josh Bleicher; Jessica N Cohan; Lyen C Huang; William Peche; T Bartley Pickron; Courtney L Scaife; Tawnya L Bowles; John R Hyngstrom; Elliot A Asare Journal: World J Gastroenterol Date: 2021-01-21 Impact factor: 5.742
Authors: Ruth P Norris; Rosie Dew; Linda Sharp; Alastair Greystoke; Stephen Rice; Kristina Johnell; Adam Todd Journal: BMC Med Date: 2020-10-23 Impact factor: 8.775